NTRK1 Inhibitors
8 drugsAbout NTRK1
NTRK1 (also known as NTRK, TRK, or TrkA) is a protein kinase receptor. It plays a role in nerve growth factor signaling and is involved in cell growth and differentiation.
NTRK1 is a validated oncology target, supported by strong genetic evidence (max score 0.94) linking it to diseases like hereditary sensory and autonomic neuropathy. Loss-of-function variants increase disease risk, suggesting activation may be beneficial.
NTRK1 is targeted by 8 FDA-approved drugs, including VITRAKVI, STIVARGA, and ROZLYTREK, primarily small molecules (7 drugs). These drugs span oncology (3 drugs) and other therapeutic areas (5 drugs).
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 80% attractiveness score.
- White space opportunity in Advanced Malignant Solid Neoplasm with only 4 trials.
Human Genetic Evidence Strong
NTRK1 has strong genetic support with a max score of 0.94, linking it to 5 diseases.
Strong genetic support suggests high confidence in target validation and increased likelihood of clinical success.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 2 traits
- • Strong signal in nervous system disease, phenotype, genetic, familial or congenital disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
5 totalGWAS and other genetic studies link NTRK1 to 5 diseases.
Loss-of-function causes disease; activation may help
Loss-of-function causes disease; activation may help
🔗 Colocalization Evidence 9 strong
max H4: 0.97eQTL/pQTL signals for NTRK1 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
Seven companies have approved NTRK1-targeting drugs, with Roche and Bayer among the top players.
The presence of multiple companies indicates a competitive market, requiring differentiated strategies for new entrants.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| GAVRETO | RIGEL PHARMS | 2020 | 2 |
| ROZLYTREK | Roche | 2019 | 2 |
| OXERVATE | DOMPE FARMACEUTICI | 2018 | 1 |
| LORBRENA | Pfizer | 2018 | 1 |
| IBTROZI | NUVATION | 2025 | 1 |
Drug Modality Landscape
Modalities
Routes of Administration
NTRK1 is druggable by both biologics (1) and small molecules (7), indicating broad therapeutic accessibility.
The prevalence of small molecules suggests opportunities for novel biologic modalities like antibodies or cell therapies.
📈 Modality Evolution
Small molecules pioneered NTRK1 targeting (2012), with other biologics entering more recently (2018).
Clinical Trials 417 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 114 | 75 | 16 | 22 | 82% |
| Phase 2 | 192 | 69 | 27 | 94 | 72% |
| Phase 3 | 87 | 52 | 10 | 25 | 84% |
| Phase 4 | 24 | 12 | 3 | 9 | 80% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved NTRK1 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting NTRK1. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2012 - 2025)
The first NTRK1-targeting drug was approved in 2012, with the most recent approval in 2025, spanning 14 years.
Continued approvals suggest sustained interest in NTRK1, but increasing competition may lead to market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 7 companies competing
- • Market share by company
Full Drug Portfolio
- • All 8 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 8-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 322 clinical trials targeting NTRK1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities